The two basic steps involved were an initial destruction of one or both TP53 alleles in TP53-wildtype MM cells via the CRISPR/Cas9 method, followed by concerted introduction of cDNA-expression cassettes for wildtype + mutant p53 via the Sleeping Beauty transposon system (Fig. 1a). This evidence concerns the gene TP53 and Miyoshi myopathy.